Compare NIC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NIC | AUPH |
|---|---|---|
| Founded | 2000 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | N/A | 1999 |
| Metric | NIC | AUPH |
|---|---|---|
| Price | $123.74 | $16.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $155.33 | $17.25 |
| AVG Volume (30 Days) | 126.0K | ★ 1.2M |
| Earning Date | 01-20-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 18.84 | N/A |
| EPS | ★ 9.34 | 0.55 |
| Revenue | ★ $375,962,000.00 | $265,808,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | $4.72 | $16.45 |
| P/E Ratio | ★ $13.23 | $29.54 |
| Revenue Growth | 9.68 | ★ 20.62 |
| 52 Week Low | $97.90 | $6.55 |
| 52 Week High | $141.92 | $16.54 |
| Indicator | NIC | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.81 | 63.13 |
| Support Level | $129.79 | $16.00 |
| Resistance Level | $132.84 | $16.54 |
| Average True Range (ATR) | 3.10 | 0.41 |
| MACD | -0.87 | -0.03 |
| Stochastic Oscillator | 4.99 | 80.58 |
Nicolet Bankshares Inc is a United States-based bank holding company's principal business is banking, consisting of lending and deposit gathering, as well as ancillary banking-related products and services, to businesses and individuals of the communities it serves, and the operational support to deliver, fund and manage. It offers a variety of loans, deposits, and related services to business customers especially small and medium-sized businesses and professional concerns, business deposit products, cash management services, international banking services, business loans, lines of credit, commercial real estate financing, construction loans, agricultural real estate or production loans, and letters of credit, as well as retirement plan services.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.